Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.

Today’s we’re highlighting U.S. biotechs focused on Parkinson’s that also have enough balance sheet strength to keep funding their programs as macroeconomic conditions have become more challenging.

Below are three names that stand out for both their clinical progress and financial positioning.

1. Gain Therapeutics (GANX)

Overview: Gain Therapeutics is a Bethesda-based biotech developing drugs that aim to do something no Parkinson’s treatment has done yet: slow or change the disease itself, rather than just manage symptoms.

It uses its Magellan platform to design small-molecule drugs that target hidden sites on disease-related proteins. Its lead candidate, GT-02287, is currently in a Phase 1b trial as an oral treatment for Parkinson’s, designed to address the underlying biology of the disease.

Market cap: US$88.3 million

For investors:

Early results are encouraging. The company has reported improvements in both key biomarkers and patient motor function, suggesting the drug may be doing more than just treating symptoms.

But there’s a trade-off. The company generates no revenue, is losing roughly US$20 million annually, and has already flagged going concern risks. It will likely need to raise more capital before its planned Phase 2 readout.

GT-02287’s early Parkinson’s signals and full worldwide rights to 2038 could mean the current share price is only telling part of the story. One Simply Wall St community narrative highlights a ~US$4 billion Parkinson’s market compared to Gain’s sub-US$100 million valuation, pointing to a gap between potential and current pricing.

With Phase 2 trials expected to begin in Q3 2026, the next set of results could be a key turning point.

2. Annovis Bio (ANVS)

Overview: Annovis Bio is a clinical-stage biotech focused on neurodegenerative diseases. Its lead drug, buntanetap, is in Phase 3 trials for Alzheimer’s and an open-label Phase 3 study for Parkinson’s, alongside programs in brain injury, stroke, and dementia.

Market Cap: US$64.2 million

For investors: Annovis sits at the intersection of a very small valuation and very ambitious clinical goals. On one hand, it has a late-stage Alzheimer’s program that has passed a key safety review, along with a large Parkinson’s study using wearable tech to track digital biomarkers. On the other, it has no revenue, reported a US$28.9 million net loss in 2025, and remains heavily reliant on external funding.

Recent equity raises, a CFO departure, and going concern flags only add to the execution risk.

That tension is exactly what makes this one interesting: a potentially valuable late-stage asset set against very real financing and operational hurdles.

Buntanetap’s late stage potential, set against a US$64.2 million valuation and going concern flags, raises a sharp question: what are investors missing in the 1 key reward and 4 important warning signs (2 are major!)?

3. Anavex Life Sciences (AVXL)

Overview: Anavex is a New York–based clinical-stage biotech company developing oral precision-medicine drugs like blarcamesine and ANAVEX 3-71 for Alzheimer’s, Parkinson’s, Rett syndrome and other central nervous system disorders, aiming to treat underlying disease biology rather than just symptoms.

Market Cap: US$324.35 million

For investors: Anavex stands out for one reason: balance sheet strength. With US$131.7 million in cash, no debt, and an estimated runway of more than three years, it’s in a stronger position than most pre-revenue biotechs. That gives it time to execute across a broad CNS pipeline.

Still, risks remain. The company continues to post losses and has faced regulatory setbacks, including a negative opinion from Europe’s CHMP on its lead drug.

At the same time, ongoing engagement with regulators and new precision medicine data keep multiple pathways open. Some analyst models even point to meaningful revenue and earnings by 2029. The question for investors is how much of that future is already reflected in today’s price, and how much depends on execution from here.

Anavex’s cash runway and broad CNS pipeline could be masking what consensus models are really implying about its future. See how the analyst forecasts for Anavex Life Sciences stack up against today’s price before one detail changes everything

You’ve only seen a handful of names here. The full Top US Biotechs Developing Parkinson’s Therapies screener includes 11 more companies working on similar ideas.

Each comes with its own mix of clinical progress, cash runway, and risk. Using Simply Wall St, you can filter for the ones that best match what you’re looking for, so you can focus on the opportunities that fit your strategy.

Take Control of Your Investment Journey

If Gain Therapeutics or any of these companies stand out, you can get started for free with Simply Wall St.

Add your top picks to a Watchlist to track their share price against fair value and spot potential entry points. Once you’ve invested, use the Portfolio Command Center to stay on top of the updates that matter, without the noise.

You can also explore our Community, where investors share their thinking, helping you uncover risks, catalysts, and ideas you might have missed.

Looking beyond Parkinson’s?

Fresh ideas do not stay under the radar for long, and the best entry points can vanish once momentum takes off, so scan these breakouts before the crowd and consider your options promptly.

If you’re exploring other ideas, here are a few places to start:

1. Dividend stability: Scan 13 “dividend fortresses” built to deliver income across different market conditions
2. Early-stage growth: Discover 32 under-the-radar AI small caps before they attract wider attention
3. Long-term compounders: Explore 42 companies with strong balance sheets and fundamentals, built for durability over time

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.